Skip to content
Search

Latest Stories

NHS commissions RPS to develop sustainability guidance for pharmacy

NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment.

The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions.


“I’m delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams,” RPS president Professor Claire Anderson said.

“Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving ‘net zero’ emissions by 2040.”

Peter Morgan, medicines assistant director at NHS England, commented: “Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices.”

The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.

Key elements will include advice on medicines supply, usage and disposal as well as influencing service users with information on how to improve compliance and change from high-carbon products to lower environmental impact alternatives where appropriate.

The guidance will prompt simple measures that all teams can take to be accredited and mark their sustainability status and encourage further action to build on work underway.

“We want to support teams to identify areas where they can make sustainable changes to decrease the environmental impact of the services and clinical care they provide. Pharmacy can make a huge contribution to the goal of making health services more environmentally sustainable and this guidance and accreditation scheme will help us all move towards ‘net zero’,” Elen Jones, director lead for the RPS environmental sustainability programme, said.

Minna Eii, co-founder of Pharmacy Declares and lead author for the RPS guidance, added: “Many staff and organisations in the UK are looking for ways to reduce their environmental impacts but are unsure where to start. This pharmacy green accreditation scheme will be a great tool for all pharmacies to help the NHS meet its ‘net zero’ ambition and guide individuals that are just starting on this journey.”

The guidelines will be drafted after a literature search and a consultation will run during October for feedback. The guidance will then be piloted and the full scheme will launch by Spring 2024.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less